Harlan F. Weisman

Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis

Harlan F. Weisman, Michelle K. Leppo, Henry C. Marsh et al. · Science · 1990 · 979 citations

Life Sciences, Immunology, Pharmacology +17

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

Eric J. Topol, R.M. Califf, Harlan F. Weisman et al. · The Lancet · 1994 · 841 citations

Medicine, Cardiology, Surgery +16

Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.

Giuseppe Ambrosio, Harlan F. Weisman, J A Mannisi et al. · Circulation · 1989 · 463 citations · Full text

Medicine, Cardiology, Hemodynamic Management +9

Pathophysiology and pathogenesis of stunned myocardium. Depressed Ca2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts.

Hideo Kusuoka, James K. Porterfield, Harlan F. Weisman et al. · Journal of Clinical Investigation · 1987 · 426 citations · Full text

Life Sciences, Cardiology, Physiology +15

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

James E. Tcheng, Stephen G. Ellis, Barry S. George et al. · Circulation · 1994 · 415 citations · Full text

Medicine, Cardiology, Pharmacology +17